Shots:
- The NMPA has approved Byvasda for the treatment of adult recurrent Glioblastoma which is the third approved indication of Byvasda in China
- The launch of Byvasda has provided Chinese patients with high quality and relatively more affordable bevacizumab biosimilar injection
- Byvasda is a bevacizumab biosimilar and a recombinant humanized anti-VEGF monoclonal antibody drug. Byvasda has been approved in China for the treatment of NSCLC and mCRC
Click here to read full press release/ article | Ref: Innovent | Image: MediCircle
The post Innovent’s Byvasda (Bevacizumab Biosimilar) Receive NMPA’s Approval for Adult Recurrent Glioblastoma first appeared on PharmaShots.
